Abstract
BACKGROUND: In patients with primary pulmonary hypertension who respond to vasodilators acutely, survival can be improved by the long term use of calcium channel blockers. However, testing for such a response with calcium channel blockers or prostacyclin (PGI2) may cause hypotension and adversely affect gas exchange. Nitric oxide (NO), which does not have these effects, could be a better test agent. METHODS: NO (10, 20, and 40 ppm for 15 minutes), PGI2 (1-->10 ng/kg/min), and oral nifedipine (10 mg, then 20 mg/h) were administered sequentially to 10 patients after determination of the 24 hour spontaneous variability of their pulmonary and systemic mean arterial pressures. Patients were considered responders if the mean pulmonary artery pressure or pulmonary vascular resistance decreased by 20% or more. RESULTS: Six patients (60%) responded to all three agents, and three to none of the agents. One patient responded to PGI2 only. In those who responded to vasodilators, NO had no major effect on gas exchange or systemic haemodynamics, while PGI2 and nifedipine both induced systemic hypotension (mean (SD) systemic arterial pressure 72 (14) versus 89 (19) mm Hg with PGI2 and 72 (15) versus 86 (17) mm Hg with nifedipine, p < 0.05) and hypoxaemia (PaO2 8.7 (1.4) versus 10.8 (1.0) kPa with PGI2 and 8.6 (1.4) versus 10.2 (1.5) kPa with nifedipine, p < 0.05) and increased venous admixture (28 (9) versus 14 (4)% with PGI2 and 22 (9) versus 13 (5)% with nifedipine, p < 0.05). CONCLUSIONS: NO inhalation can accurately predict a vasodilator response to nifedipine in patients with severe pulmonary hypertension without adverse effects on systemic haemodynamics and gas exchange. This absence of side effects may make it a more appropriate agent for testing the vasodilator response.
Full Text
The Full Text of this article is available as a PDF (149.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Lynch J. P., Mhyre J. G., Dantzker D. R. Influence of cardiac output on intrapulmonary shunt. J Appl Physiol Respir Environ Exerc Physiol. 1979 Feb;46(2):315–321. doi: 10.1152/jappl.1979.46.2.315. [DOI] [PubMed] [Google Scholar]
- Palevsky H. I., Long W., Crow J., Fishman A. P. Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension. Circulation. 1990 Dec;82(6):2018–2026. doi: 10.1161/01.cir.82.6.2018. [DOI] [PubMed] [Google Scholar]
- Partanen J., Nieminen M. S., Luomanmäki K. Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine. N Engl J Med. 1993 Sep 9;329(11):812–813. doi: 10.1056/NEJM199309093291117. [DOI] [PubMed] [Google Scholar]
- Rich S., Brundage B. H. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation. 1987 Jul;76(1):135–141. doi: 10.1161/01.cir.76.1.135. [DOI] [PubMed] [Google Scholar]
- Rich S., Dantzker D. R., Ayres S. M., Bergofsky E. H., Brundage B. H., Detre K. M., Fishman A. P., Goldring R. M., Groves B. M., Koerner S. K. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987 Aug;107(2):216–223. doi: 10.7326/0003-4819-107-2-216. [DOI] [PubMed] [Google Scholar]
- Rich S., Kaufmann E., Levy P. S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992 Jul 9;327(2):76–81. doi: 10.1056/NEJM199207093270203. [DOI] [PubMed] [Google Scholar]
- Sitbon O., Brenot F., Denjean A., Bergeron A., Parent F., Azarian R., Herve P., Raffestin B., Simonneau G. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 1):384–389. doi: 10.1164/ajrccm.151.2.7842196. [DOI] [PubMed] [Google Scholar]
- Sprague R. S., Stephenson A. H., Lonigro A. J. Prostaglandin I2 supports blood flow to hypoxic alveoli in anesthetized dogs. J Appl Physiol Respir Environ Exerc Physiol. 1984 May;56(5):1246–1251. doi: 10.1152/jappl.1984.56.5.1246. [DOI] [PubMed] [Google Scholar]
- Weir E. K., Rubin L. J., Ayres S. M., Bergofsky E. H., Brundage B. H., Detre K. M., Elliott C. G., Fishman A. P., Goldring R. M., Groves B. M. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis. 1989 Dec;140(6):1623–1630. doi: 10.1164/ajrccm/140.6.1623. [DOI] [PubMed] [Google Scholar]